SemaThera

OverviewSuggest Edit

SemaThera is a spin-off company from AmorChem Venture Fund 1, focusing on SEMA 3A protein inhibitor in the treatment of ocular diseases, such as diabetic macular edema. This technology emerges from the laboratory of Dr Mike Sapieha, Hôpital Maisonneuve-Rosement (Montreal, Canada).
TypePrivate
Founded2016
HQWestmount, CA
Websitesemathera.com

Latest Updates

Employees (est.) (Sept 2020)7(-12%)
Cybersecurity ratingAMore

Key People/Management at SemaThera

Garth Cumberlidge

Garth Cumberlidge

President & CEO
Maxime Ranger

Maxime Ranger

Chairman of the Board
Véronique Bougie

Véronique Bougie

Chief Operating Officer
Mike Sapieha

Mike Sapieha

Founder & Chief Scientific Officer
Show more

SemaThera Office Locations

SemaThera has an office in Westmount
Westmount, CA (HQ)
1 Carré Westmount #800
Show all (1)

SemaThera Financials and Metrics

Summary Metrics

Founding Date

2016

SemaThera total Funding

$1 m

SemaThera latest funding size

$1 m

Time since last funding

4 years ago
SemaThera's latest funding round in January 2017 was reported to be $1 m. In total, SemaThera has raised $1 m
Show all financial metrics

SemaThera Cybersecurity Score

Cybersecurity ratingPremium dataset

A

92/100

SecurityScorecard logo

SemaThera Online and Social Media Presence

Embed Graph

SemaThera News and Updates

SemaThera Frequently Asked Questions

  • When was SemaThera founded?

    SemaThera was founded in 2016.

  • Who are SemaThera key executives?

    SemaThera's key executives are Garth Cumberlidge, Maxime Ranger and Véronique Bougie.

  • How many employees does SemaThera have?

    SemaThera has 7 employees.

  • Who are SemaThera competitors?

    Competitors of SemaThera include Adaptimmune, Harbour Antibodies and GrayBug.

  • Where is SemaThera headquarters?

    SemaThera headquarters is located at 1 Carré Westmount #800, Westmount.

  • Where are SemaThera offices?

    SemaThera has an office in Westmount.

  • How many offices does SemaThera have?

    SemaThera has 1 office.